INVO Bioscience, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by INVO Bioscience, Inc. (the "Company") on January 17, 2019, reporting events occurring on January 14, 2019. The Company, incorporated in Nevada, specializes in reproductive technology, specifically its proprietary intravaginal culture device known as INVOcell.
Key Financial Metrics and Transaction Details
The filing details the consummation of a Distribution Agreement with Ferring International Center S.A. ("Ferring"). Key financial terms include:
- Initial License Fee: The Company received an upfront payment of $5,000,000 upon closing.
- Contingent Payment: Ferring is obligated to pay an additional $3,000,000 if the Company obtains a five-day label enhancement from the FDA for the incubation period at least three years prior to the license expiration.
- Supply Revenue: Ferring will pay a specified supply price for each Licensed Product purchased under a separate Supply Agreement.
- Liquidity and Cash Flow: The filing confirms the receipt of the $5,000,000 cash payment. No other revenue, profit, debt, or liquidity metrics are provided in this specific filing.
Material Changes and Agreement Terms
The primary material change is the execution of the exclusive U.S. distribution rights for the INVOcell device. Key terms include:
- Exclusive License: Ferring holds exclusive rights to market, promote, distribute, and sell the Licensed Product in the United States for reproductive technology uses.
- Company Retention: The Company retains rights to establish up to five clinics in the U.S. and holds all commercialization rights outside the United States.
- Term: The initial term expires on December 31, 2025. It may be terminated by the Company if Ferring fails to meet minimum revenue thresholds in the final two years. Otherwise, it auto-renews for successive three-year terms.
- Termination: The agreement allows for termination for material breach or by Ferring for convenience.
Outlook, Risks, and Management Commentary
Management highlighted the strategic partnership with Ferring to commercialize the Licensed Product in the U.S. market. The filing notes that Ferring is responsible for all commercialization activities at its own cost. Risks associated with the agreement include:
- Failure to obtain the FDA label enhancement required for the $3,000,000 contingent payment.
- Potential termination by Ferring for convenience or due to failure to meet minimum revenue targets.
- Reliance on Ferring for U.S. commercialization success.
The filing does not provide specific forward-looking financial guidance or projections beyond the contractual obligations.
Key Facts for Investor Verification
- Verify the receipt and accounting treatment of the $5,000,000 initial license fee in the Company's upcoming financial statements.
- Monitor the Company's progress in obtaining the FDA five-day label enhancement required to trigger the $3,000,000 milestone payment.
- Review the specific "minimum revenues" thresholds defined in the full Distribution Agreement that could allow the Company to terminate the deal in 2025.
- Confirm the terms of the separate Supply Agreement regarding the per-unit price Ferring will pay for the Licensed Product.